The global oncology molecular diagnostics market reached a value of US$ 3.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.3 Billion by 2027, exhibiting a CAGR of 14.7% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Oncology molecular diagnostics identify the presence of cancer cells by analyzing their biological molecules. Several tests are performed on the blood, saliva, and tumor tissue samples for detecting and measuring specific genetic sequences in the DNA, RNA, and cell proteins. Oncology molecular diagnostics help perform rapid analysis and provide detailed information that is further utilized in the personalized treatment of cancer. These diagnostics solutions find application in clinical and point-of-care (POC) testing for early detection of cancer. They are also used in blood banks to identify pathogens and infectious diseases present in the donated blood samples.

The rising prevalence of cancer on account of changing lifestyles, growing geriatric population, and the increasing trend of smoking represents one of the major factors impelling the global oncology molecular diagnostics market growth. Apart from this, the escalating demand for rapid and accurate diagnosis, along with advancements in next generation sequencing (NGS) techniques, is contributing to the growth of the market. Furthermore, a rise in the number of individuals suffering from viral and bacterial infections and the increasing participation in blood donation campaigns is positively influencing the demand for oncology molecular diagnostics worldwide. However, due to the sudden outbreak of the coronavirus disease (COVID-19), several healthcare institutions are undertaking steps to mitigate the risk of the pandemic on cancer patients by reducing the number of medical appointments. Moreover, regular screening for cancer patients has witnessed a decline due to the repurposing of diagnostics resources for providing COVID-19 testing and consequent reduction in oncology testing.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology molecular diagnostics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on cancer type, product, technology and end-user.

Breakup by Cancer Type:

Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Blood Cancer

Breakup by Product:


Breakup by Technology:

Polymerase Chain Reaction (PCR)
In Situ Hybridization
Chips and Microarrays
Isothermal Nucleic Acid Amplification Technology (INAAT)
Mass Spectrometry
DNA and NGS Sequencing
Transcription Mediated Amplification (TMA)

Breakup by End-User:

Hospitals and Clinics
Reference Laboratories

Breakup by Region:

North America
United States
Asia Pacific
South Korea
United Kingdom
Latin America
Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies, Inc., Abbott Laboratories, Bayer AG, Becton, Dickinson and Company, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic, Inc., Qiagen N.V., Siemens Healthcare and Sysmex Corporation.

Key questions answered in this report:

How has the global oncology molecular diagnostics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global oncology molecular diagnostics market?
What are the key regional markets?
What is the breakup of the market based on the cancer type?
What is the breakup of the market based on the product?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the end-user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global oncology molecular diagnostics market and who are the key players?
What is the degree of competition in the industry?